Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.66 |
| ▸ | FNTB | P49356 | 14/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667242 | 0.81 | FNTA (0.65) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL11947168 | 0.79 | FNTA (1.00) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL6843800 | 0.79 | FNTA (1.00) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL1682773 | 0.79 | FNTA (0.67) | FNTAFNTBCYP3A4 | |
| SCHEMBL5656663 | 0.78 | FNTA (1.00) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL13529079 | 0.76 | FNTA (0.68) | FNTAFNTBCYP3A4PGGT1B | |
| Oxalic Acid SCHEMBL5512297 | 0.76 | FNTA (0.92) | FNTAFNTBCYP3A4PGGT1B | |
| Hydrochloric Acid SCHEMBL1538309 | 0.75 | FNTA (0.63) | FNTAFNTBCYP3A4 | |
| SCHEMBL5736481 | 0.74 | FNTA (0.61) | FNTAFNTBCYP3A4 | |
| Hydrochloric Acid SCHEMBL6807778 | 0.74 | FNTA (0.55) | FNTAFNTBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157773-A1 | Farnesyl protein transferase inhibitors for treating cachexia | JANSSEN PHARMACEUTICA INC. | 2004-08-12 | — | — | US | claimed |
| US-20040157773-A1 | Farnesyl protein transferase inhibitors for treating cachexia | JANSSEN PHARMACEUTICA INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157773-A1 | Farnesyl protein transferase inhibitors for treating cachexia | FNTA, FNTB, FABP1 | FNTA 1/4885FNTB 2/4885CYP3A4 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.